204 related articles for article (PubMed ID: 25111512)
1. Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.
Yoon JH; Kim HJ; Kim JW; Jeon YW; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Min WS; Park CW
Bone Marrow Transplant; 2014 Dec; 49(12):1466-74. PubMed ID: 25111512
[TBL] [Abstract][Full Text] [Related]
2. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
3. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
[TBL] [Abstract][Full Text] [Related]
4. Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Shin HJ; Min WS; Min YH; Cheong JW; Lee JH; Kim IH; Hong DS; Ahn JS; Kim HJ; Lee WS; Jung CW; Jang JH; Park Y; Kim HJ;
Ann Hematol; 2019 May; 98(5):1135-1147. PubMed ID: 30758645
[TBL] [Abstract][Full Text] [Related]
5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
7. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
8. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
9. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract][Full Text] [Related]
10. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
12. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
15. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.
Kuwatsuka Y; Miyamura K; Suzuki R; Kasai M; Maruta A; Ogawa H; Tanosaki R; Takahashi S; Koda K; Yago K; Atsuta Y; Yoshida T; Sakamaki H; Kodera Y
Blood; 2009 Feb; 113(9):2096-103. PubMed ID: 19126873
[TBL] [Abstract][Full Text] [Related]
17. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].
Wu TM; Xue SL; Li Z; Yu JQ; Wang J; Wang BR; Wan CL; Shen XD; Qiu QC; Bao XB; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):646-653. PubMed ID: 34547870
[No Abstract] [Full Text] [Related]
19. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
Hospital MA; Prebet T; Bertoli S; Thomas X; Tavernier E; Braun T; Pautas C; Perrot A; Lioure B; Rousselot P; Tamburini J; Cluzeau T; Konopacki J; Randriamalala E; Berthon C; Gourin MP; Recher C; Cahn JY; Ifrah N; Dombret H; Boissel N
Blood; 2014 Aug; 124(8):1312-9. PubMed ID: 25006122
[TBL] [Abstract][Full Text] [Related]
20. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
